JP5185826B2 - ウイルス性肝炎の処置 - Google Patents

ウイルス性肝炎の処置 Download PDF

Info

Publication number
JP5185826B2
JP5185826B2 JP2008549616A JP2008549616A JP5185826B2 JP 5185826 B2 JP5185826 B2 JP 5185826B2 JP 2008549616 A JP2008549616 A JP 2008549616A JP 2008549616 A JP2008549616 A JP 2008549616A JP 5185826 B2 JP5185826 B2 JP 5185826B2
Authority
JP
Japan
Prior art keywords
interferon
patient
nitazoxanide
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008549616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522371A5 (cg-RX-API-DMAC7.html
JP2009522371A (ja
Inventor
ジャン−フランソワ ロシニョール,
Original Assignee
ロマーク ラボラトリース,エル.シー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロマーク ラボラトリース,エル.シー. filed Critical ロマーク ラボラトリース,エル.シー.
Publication of JP2009522371A publication Critical patent/JP2009522371A/ja
Publication of JP2009522371A5 publication Critical patent/JP2009522371A5/ja
Application granted granted Critical
Publication of JP5185826B2 publication Critical patent/JP5185826B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2008549616A 2006-01-09 2007-01-09 ウイルス性肝炎の処置 Expired - Fee Related JP5185826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
US60/757,036 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009293398A Division JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Publications (3)

Publication Number Publication Date
JP2009522371A JP2009522371A (ja) 2009-06-11
JP2009522371A5 JP2009522371A5 (cg-RX-API-DMAC7.html) 2010-02-18
JP5185826B2 true JP5185826B2 (ja) 2013-04-17

Family

ID=38257004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008549616A Expired - Fee Related JP5185826B2 (ja) 2006-01-09 2007-01-09 ウイルス性肝炎の処置
JP2009293398A Pending JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009293398A Pending JP2010070566A (ja) 2006-01-09 2009-12-24 ウイルス性肝炎の処置

Country Status (17)

Country Link
US (3) US8633230B2 (cg-RX-API-DMAC7.html)
EP (1) EP1976516B9 (cg-RX-API-DMAC7.html)
JP (2) JP5185826B2 (cg-RX-API-DMAC7.html)
CN (1) CN101448497B (cg-RX-API-DMAC7.html)
AP (1) AP2907A (cg-RX-API-DMAC7.html)
AU (1) AU2007204963B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706379A2 (cg-RX-API-DMAC7.html)
CA (1) CA2636527C (cg-RX-API-DMAC7.html)
DK (1) DK1976516T3 (cg-RX-API-DMAC7.html)
EA (1) EA015560B1 (cg-RX-API-DMAC7.html)
ES (1) ES2422556T3 (cg-RX-API-DMAC7.html)
IL (1) IL192548A (cg-RX-API-DMAC7.html)
MX (1) MX2008008723A (cg-RX-API-DMAC7.html)
NZ (1) NZ569507A (cg-RX-API-DMAC7.html)
UA (1) UA100840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007081974A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806310B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
CA2694440A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
AU2010226857B2 (en) 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
HK1250945A1 (zh) 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
SI3442580T1 (sl) * 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
EP3573614B1 (en) * 2017-01-27 2024-11-20 Genfit Pharmaceutical compositions for combination therapy
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
US11547699B2 (en) 2017-11-17 2023-01-10 Hubert Köster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
US12208087B2 (en) 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニドおよび2-ヒドロキシ-n-(5-クロロ-1,3-チアゾル-2-イル)ベンズアミド(rm-4848)とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびn-メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
KR20240006588A (ko) * 2021-05-11 2024-01-15 장피트 패혈증의 치료에서의 니타족사나이드
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
SI0755386T1 (en) * 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
SI20149B (en) 1997-05-07 2001-08-31 Romark Lab Lc Pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
DE69901321T2 (de) * 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
US5925622A (en) 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1562617B1 (en) 2002-10-29 2006-12-20 Council of Scientific and Industrial Research New use of pipataline
US7081260B2 (en) 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Also Published As

Publication number Publication date
CA2636527C (en) 2016-05-17
US8633230B2 (en) 2014-01-21
AU2007204963A1 (en) 2007-07-19
CN101448497B (zh) 2013-07-10
CN101448497A (zh) 2009-06-03
US20140112888A1 (en) 2014-04-24
AP2907A (en) 2014-05-31
UA100840C2 (ru) 2013-02-11
ES2422556T3 (es) 2013-09-12
EP1976516B9 (en) 2013-10-30
CA2636527A1 (en) 2007-07-19
BRPI0706379A2 (pt) 2011-03-22
AP2008004550A0 (en) 2008-08-31
JP2010070566A (ja) 2010-04-02
IL192548A0 (en) 2009-02-11
WO2007081974A2 (en) 2007-07-19
EA015560B1 (ru) 2011-08-30
EA200870164A1 (ru) 2008-12-30
EP1976516B1 (en) 2013-04-24
JP2009522371A (ja) 2009-06-11
HK1123733A1 (en) 2009-06-26
WO2007081974A3 (en) 2008-01-17
USRE47404E1 (en) 2019-05-28
ZA200806310B (en) 2009-12-30
US20070167504A1 (en) 2007-07-19
AU2007204963B2 (en) 2012-09-27
IL192548A (en) 2015-08-31
US9107913B2 (en) 2015-08-18
DK1976516T3 (da) 2013-07-15
EP1976516A2 (en) 2008-10-08
NZ569507A (en) 2011-11-25
MX2008008723A (es) 2008-09-26
EP1976516A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
USRE47404E1 (en) Viral hepatitis treatment
JP2009522371A5 (cg-RX-API-DMAC7.html)
JP5539363B2 (ja) インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
JP2008530124A (ja) フラビウイルス感染症を処置または予防するための組成物および方法
US20100260755A1 (en) Ibudilast and immunomodulators combination
US20190091207A1 (en) Treatment Of CDKL5 Disorders With GSK3B Inhibitor Tideglusib
JP2013508425A (ja) Bi201335、インターフェロンアルファおよびリバビリンを含むhcvの併用療法のための投薬処置計画
US11007178B2 (en) Methods and uses of Nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof
US20240342211A1 (en) Short-term activated dc1s and methods for their production and use
WO2010009762A1 (en) Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
HK1123733B (en) Viral hepatitis treatment
CN112569359A (zh) 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
JP5527549B2 (ja) C型肝炎治療剤
JP2013018729A (ja) アルツハイマー病治療剤の作用増強経口用剤
CN1364089A (zh) Cml的治疗
HK1185808A1 (zh) 用於治疗癌症的包含威罗菲尼和干扰素的组合疗法
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c
JP2006232862A (ja) 代償不全肝疾患の患者の治療のための組成物

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20121005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121009

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130118

R150 Certificate of patent or registration of utility model

Ref document number: 5185826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees